RUNX1 and leukemia: Survival analysis revealed that primary YCU-AML1 mice had significantly impaired survival compared with age-matched controls (median survival 45 days vs > 50 days, p = 0.0011), consistent with lethal leukemia development in vivo (Fig. 5C).